Sudden cardiac risk assessment in hypertrophic cardiomyopathy: role of the imaging

N.D. Oryshchyn

References

1. Руденко К.В., Лазоришинец В.В., Трембовецкая Е.М., Невмержицкая Л.А. The results of surgical treatment of patients with hypertrophic obstructive cardiomyopathy as a risk factor of sudden cardiac death. Свiт медицини та бiологiї. 2020. №16 (2). С. 104–114. doi:10.26724/2079-8334-2020-2-72-109-114.
2. Bhopalwala H, Dewaswala N, Liu S, et al. Conversion of left atrial volume to diameter for automated estimation of sudden cardiac death risk in hypertrophic cardiomyopathy. Echocardiography. 2021;38:183–8.
3. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J – Cardiovasc Imaging. 2015;16(3):280.
4. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrastenhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130:484–495.
5. Chan RH, Maron BJ, Olivotto I, et al. Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:436–41.
6. Choi EY, Rim SJ, Ha JW, et al. Phenotypic spectrum and clinical characteristics of apical hypertrophic cardiomyopathy: multicenter echo-Doppler study. Cardiology. 2008;110(1):53–61.
7. Elliott PM, Gimeno JR, Tome´ MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–41.
8. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.
9. Finocchiaro G, PapadakisM, Tanzarella G, et al. Sudden death can be the first manifestation of hypertrophic cardiomyopathy: data from a United Kingdom Pathology Registry. JACC Clin Electrophysiol. 2019;5:252–4.
10. Freitas P, Ferreira AM, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson. 2019;15;21(1):50. doi:10.1186/s12968-019-0561-4
11. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–96.
12. Greulich S, Seitz A, Herter D, Günther F, Probst S, Bekeredjian R, Gawaz M, Sechtem U, Mahrholdt H. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study. Eur Heart J – Cardiovasc Imaging. 2021;22(7):732–41. https://doi.org/10.1093/ehjci/jeaa423.
13. Klopotowski M, Kukula K, Lukasz A, et al. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68:49–56.
14. Li X, Lai L, Luo R, et al. The clinical prognosis of presence and location of late gadolinium enhancement by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a single-center cohort study. J Cardiovasc Transl Res. 2021;14(5):1001–16. DOI:10.1007/s12265-021-10107-x.
15. Maron MS, Olivotto I, Betocchi S. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
16. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation. 2006;114(15):1633–44.
17. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12.
18. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541–9.
19. Maron BJ, Casey SA, Chan RH, et al. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:757–64.
20. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583– 8.
21. Mentias A, Raeisi-Giglou P, Smedira NG. Late Gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am College of Cardiology. 2018;72(8):857–70.
22. Mills H, Espersen K, Jurlander R, et al. Prevention of sudden cardiac death in hypertrophic cardiomyopathy: risk assessment using left atrial diameter predicted from left atrial volume. Clin Cardiol. 2020;43:581–6.
23. Minami Y, Haruki S, Yashiro B, et al. Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. Cardiol. 2016;68:478–84.
24. Minami Y, Haruki S, Hagiwara N. Phenotypic overlap in hypertrophic cardiomyopathy: apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol. 2014;64(6):463–9. doi:10.1016/j.jjcc.2014.03.003. Epub 2014 Apr 24. PMID: 24768408.
25. Nguyen A, Schaff HV. Electrical storms in patients with apical aneurysms and hypertrophic cardiomyopathy with midventricular obstruction: A case series. J Thorac Cardiovasc Surg. 2017;154(6):e101–e103.
26. O’Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137:1015–23.
27. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: executive summary: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e533–e557.
28. Pozios I, Corona-Villalobos C, Sorensen LL. Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(6):938–44. doi:10.1016/j.amjcard.2015.06.018. Epub 2015 Jun 26. PMID: 26239580; PMCID: PMC4554842.
29. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017; 69:761–773.
30. Rowin EJ, Sridharan A, Madias C. Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy. Am J Cardiol. 2020;128:75–83. 
31. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;(65):1249–54.
32. Śpiewak M, Kłopotowski M, Kowalik E, et al. Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging. Sci Rep. 2021;11(1):7146. doi: 10.1038/s41598-021-86532-4. PMID: 33785804; PMCID: PMC8009882.
33. Spirito P, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85.
34. Yang H, et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr. 2005;18(10):1074–82.
35. Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016; 9:1392–1402.